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INTRODUCTION: Extra-abdominal recurrence or metastasis of a gastrointestinal stromal tumor (GIST) is
very rare. Chest wall recurrence of a resected gastric GIST is extremely rare.
PRESENTATION OF CASE: A 64-year-old Japanese man had undergone proximal gastrectomy for a gastric
submucosal tumor 11 years previously. The histopathological diagnosis was GIST (size, 8 cm). He did
not receive adjuvant therapy, and underwent imaging evaluations every 6 months for the ﬁrst 5 years
after surgery and then annually. He was admitted to our hospital because of a lump on his right anterior
chest wall 7 years after curative resection. We resected the tumor, and histopathologic ﬁndings revealed
metastatic GIST. Four years after metastasectomy, another lump appeared at a different location on the
right anterior chest wall. The patient was diagnosed with a second recurrence of gastric GIST and began
adjuvant treatmentwith imatinibafter second resection.Hehas remainedalivewithout tumor recurrence
for 2 years.
DISCUSSION: Most recurrences were predominantly found in the intra-abdominal cavity, either locally
or involving the liver or peritoneum. Extra-abdominal recurrence was much less common. Although
we assume that the recurrent tumor of our patient was derived from his gastric GIST, based on the
histopathological examinations and clinical course, it is possible that the recurrent tumor of our casewas
an “extragastrointestinal GIST”.
CONCLUSION: Because extra-abdominal recurrence can occur many years after curative resection, con-
tinued, careful whole-body follow-up is required for patients with high-risk GIST.
© 2014 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
he CCaccess article under t
. Introduction
Gastrointestinal stromal tumor (GIST) is a rare mesenchymal
umor originating from the interstitial cells of Cajal in the gastroin-
estinal tract. GIST, with a yearly incidence of 10–20 cases per 1
illion individuals. It is the most common sarcoma of the intesti-
al tract, accounting for 82% of all gastrointestinal mesenchymal
eoplasms.1,2 Themolecular, biological, and clinical characteristics
f GIST have recently been elucidated, which has led to improved
utcomes. According to the guidelines on GIST, surgical resection
 This article is publishedOpenAccess at sciencedirect.com. It is distributed under
he IJSCR Supplemental terms and conditions, which permits unrestricted non com-
ercial use, distribution, and reproduction in any medium, provided the original
uthors and source are credited.
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is the treatment of choice for resectable primary tumors;1,3,4
however, nearly half of the patients undergoing curative resection
recurred, with a 5-year recurrence-free survival (RFS) rate of 54%
and a median RFS time of 66 months.1 Several clinical trials have
indicated that adjuvant therapy after curative resection should be
administered to improve outcomes, especially for patients with
high-risk GIST.5–7
DeMatteo et al. reported that GISTs recur after resection pre-
dominantly within the abdominal cavity, either locally or in
the liver or peritoneum, and that extra-abdominal recurrence is
extremely rare.1 Furthermore, most GISTs recur during the ﬁrst 5
years of follow-up and few recur after the ﬁrst 10 years of follow-
up.7 Therefore, several risk stratiﬁcation toolshavebeendeveloped,
andmutational analysis has beenused to aid assessment of patients
for targeted adjuvant treatment.8 We herein report a patientwith a
second recurrence of gastric GIST involving his chest wall 11 years
after curative resection.
ssociates Ltd. This is an open access article under the CC BY-NC-ND license
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Fig. 1. Imaging ﬁndings. Upper gastrointestinal endoscopy shows an ulcerated submucosal tumor in the cardiac region of the stomach (A), contrast-enhanced computed
tomography (CT) shows a large mass with homogeneous density dorsal to the stomach (B), positron emission tomography/computed tomography (PET/CT) at the time of
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irst recurrence shows a mass with ﬂuorine-18 2-deoxy-2-ﬂuoro-d-glucose (FDG) a
ET-CT at the time of second recurrence shows a mass with FDG accumulation in
nterior chest wall (D).
. Presentation of case
A 64-year-old Japanese man visited our hospital complaining
f epigastralgia. An upper gastrointestinal endoscopy revealed an
lcerated submucosal tumor in the cardiac region of the stomach
Fig. 1A). Computed tomography (CT) revealed a large mass with
omogeneous density located dorsal to the stomach (Fig. 1B). The
atient hadundergone a proximal gastrectomywithout tumor rup-
ure for gastric GIST via the abdominal approach 11 years prior.
istopathological examination revealed an 8-cm GIST with lymph
ode metastases (3/9) and a mitotic count of 32/50 high-power
eld (HPF). The immunohistochemical examination showed KIT
egative and CD34 positive (Fig. 2A–C). The patient did not receive
djuvant therapy and was followed by imaging every 6 months for
he ﬁrst 5 years after surgery, and then annually.
Sevenyears after curative resection, hewas admitted to our hos-
ital because of a lump on his right anterior chest wall. Positron
mission tomography/computed tomography (PET/CT) revealed
ccumulation of ﬂuorine-18 2-deoxy-2-ﬂuoro-d-glucose (FDG) in
he tumor, with a standardized uptake value of 7.7 and no other
eﬁnitive intra-abdominal lesions (Fig. 1C).We resected the tumor,
nd histopathologic ﬁndings revealedmetastatic GIST (size, 3.5 cm;
itotic count, 80/50 HPF). Immunohistochemical examination
ound spindle-shaped cells positive for KIT and CD34 expression
Fig. 2D–F). He did not receive adjuvant therapy and underwent
maging follow-up every 6 months. Four years after his second
urgery, he developed a lump at a different location on the right
nterior chest wall. Since PET-CT revealed an FDG accumulation
n the tumor with an SUV of 7.3 and no other deﬁnitive lesions
Fig. 1D), thepatientunderwenta secondresection. Thehistopatho-
ogical diagnosis of this tumor was metastatic tumor secondary to
astric GIST. After surgery, the patient began imatinib treatment
t a dose of 400mg/day. He has been alive without recurrence on
maging for 2 years.ulation in the tumor with an SUV of 7.7 involving his right anterior chest wall (C),
mor with an SUV of 7.3 at a distance from the ﬁrst site of recurrence in his right
3. Discussion
We present a case of repeated recurrence on the chest wall
secondary to gastric GIST 11 years after curative resection of the
primary tumor. Chest wall recurrence of a resected gastric GIST
is extremely rare, although there have been a few case reports
on cutaneous and subcutaneous GIST metastases.9,10 Wang et al.
reported that all patients with cutaneous and subcutaneous GIST
metastases had multiple concurrent or subsequent abdominal
and/orhepaticmetastases.10 Wepreviously reported apatientwith
pleural dissemination of gastric GIST found 11 years after curative
resection.11 However, to the best of our knowledge, there are no
English language reports of repeated recurrence of GIST involving
the chest wall.
Most GIST recurrences occur in the abdominal cavity. DeMatteo
et al. investigated the recurrence pattern of GIST in patients who
had undergone complete resection of their primary tumor. Of the
total numberof recurrences,mostwerepredominantly found in the
intra-abdominal cavity, either locally (52%) or involving the liver
(63%) or peritoneum (21%). Extra-abdominal recurrence wasmuch
less common, and involved the lung (7%) and bone (7%).1 There
were no cases of chest wall recurrence. However, it is possible that
the recurrent tumor of our case was an “extragastrointestinal GIST
(EGIST)”. It is reported that EGIST constitutes only 5%-10% of GIST
cases.12 Most EGISTs are derived from the mesentery, omentum,
and retroperitoneum. Although our assumption that the recurrent
tumor of our patientwas derived fromhis gastric GIST, based on the
histopathological examinations and clinical course, gene mutation
analysis of the primary and recurrent lesions might provide more
information on this case.Although oral imatinib is the ﬁrst-line therapy for recurrent
or metastatic GIST, surgical treatment can be used to delay or
prevent recurrence. However, the beneﬁts of surgical resection
for recurrent cases have not been conﬁrmed.3,4,13 We performed
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Fig. 2. Histopathological ﬁndings. Hematoxylin–eosin (HE) staining of primary, ﬁrst recurrent, and second recurrent tumors shows proliferation of spindle-shaped tumor
cells (×20) (A, D, G). Immunohistochemical staining shows KIT-negative tumor cells in the primary tumor specimen and KIT-positive cells in the ﬁrst recurrent and second
recurrent tumor specimens (×20) (B, E, H). Immunohistochemical staining shows CD34-positive tumor cells in primary, ﬁrst recurrent, and second recurrent tumors (×20)
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f you have nothing to declare in any of these categories then this should be stated.
urgical resections for the 2 recurrences in our patient because
he diagnosis of recurrent GIST remained uncertain, and there
ere no other deﬁnitive recurrences except those involving the
hest wall. We believe that in our case, the second recurrence
fter tumorectomy for the ﬁrst recurrent tumor was not a local
ecurrence, because a microscopically complete resection had
een performed, and the site of the second recurrence was at a
istance from the site of the ﬁrst recurrence. It was intriguing that
he histopathological ﬁndings of the primary lesion included GIST
ith osteochrondromatous differentiation. Nada et al. reported
hat metaplastic changes resembling bone, cartilage, and adipose
ere only seen in high-risk GISTs.14 Therefore, a careful long-term
ollow-up is needed for this patient because it is possible that the
rimary tumor might have malignant potential.
The SSGXVIII/AIO trial, which was an open-label, multicenter,
andomized, phase III study, recently showed that 3 years of adju-
ant imatinib improved the recurrence-free and overall survival of
ISTpatientswhowere at ahigh risk of recurrence. Therefore, adju-
ant therapywith imatinib for at least 3 years is standard treatment
or patients with high-risk GIST.6 Our patient had not been admin-
stered adjuvant therapy after curative resection for his primary
astric GIST, because the efﬁcacy of imatinib as adjuvant therapy
as unclear at that time. Currently, a case such as ours would have
een treated by primary resection followed by adjuvant imatinib.espond to these questions/statements will mean your submission will be returned.
4. Conclusion
We report a case of repeated recurrence on the chest wall sec-
ondary to gastric GIST 11 years after curative resection of the
primary tumor. Because recurrence in unusual sites can occur
many years after curative resection, continued careful whole-body
follow-up is required for patients with high-risk GIST.
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